124 related articles for article (PubMed ID: 15015617)
1. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma.
Potti A; Ganti AK; Kargas S; Koch M
Anticancer Res; 2002; 22(5):2899-901. PubMed ID: 12530014
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
Sato O; Wada T; Kawai A; Yamaguchi U; Makimoto A; Kokai Y; Yamashita T; Chuman H; Beppu Y; Tani Y; Hasegawa T
Cancer; 2005 May; 103(9):1881-90. PubMed ID: 15772959
[TBL] [Abstract][Full Text] [Related]
4. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
[TBL] [Abstract][Full Text] [Related]
7. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
9. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical determination of HER-2/neu in malignant melanoma.
Potti A; Hille R; Koch M
Anticancer Res; 2003; 23(5A):4067-9. PubMed ID: 14666720
[TBL] [Abstract][Full Text] [Related]
11. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
Potti A; Moazzam N; Tendulkar K; Javed NA; Koch M; Kargas S
Anticancer Res; 2003; 23(5A):4023-6. PubMed ID: 14666713
[TBL] [Abstract][Full Text] [Related]
13. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma.
Potti A; Ganti AK; Koch M; Levitt R; Mehdi SA
Leuk Lymphoma; 2002 Dec; 43(12):2427-30. PubMed ID: 12613538
[TBL] [Abstract][Full Text] [Related]
15. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
17. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.
Potti A; Ganti AK; Tendulkar K; Sholes K; Chitajallu S; Koch M; Kargas S
J Cancer Res Clin Oncol; 2004 Jan; 130(1):52-6. PubMed ID: 14600832
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Kostopoulos I; Arapantoni-Dadioti P; Gogas H; Papadopoulos S; Malamou-Mitsi V; Scopa CD; Markaki S; Karagianni E; Kyriakou V; Margariti A; Kyrkou E; Pavlakis K; Zaramboukas T; Skordalaki A; Bourli A; Markopoulos C; Pectasides D; Dimopoulos MA; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2006 Apr; 96(3):251-61. PubMed ID: 16538542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
